Monoclonal antibodies were introduced to clinical practice in 1980s and play a vital role in a variety of diseases and clinical interventions including cancer, inflammatory disease, and ophthalmologic disease. There is a lack of substantial research or evidence on the effect of occupational exposure on staff, leading many staff to have significant concerns about what is a safe level of exposure, especially given their increasing availability and use. This report describes a case in which a nurse became sensitised to monoclonal antibodies as a result of preparing and administering them in a clinical area, and the subsequent actions taken in response to the incident to reduce the risk to staff.
SuzukiMCatoCCatoA.Therapeutic antibodies: their mechanisms of action and the pathological findings they induce in toxicity studies.J Toxicol Pathol2015;
28: 133–139.
2.
HalsenGKramerI.Assessing the risk to health care staff from long-term exposure to anticancer drugs – the case of monoclonal antibodies.J Oncol Pharm Pract2010;
17: 68–80.
3.
KingJAlexanderMByrneJ, et al.
A review of the evidence for occupational exposure risks to novel anticancer agents – a focus on monoclonal antibodies.J Oncol Pharm Pract2016;
22:121–134.
4.
NHS Pharmaceutical Quality Assurance Committee. Guidance on the safe handling of monoclonal antibody (mAb) products. 5th ed.
London:
NHS Pharmaceutical Quality Assurance Committee, 2015.
5.
LangfordSFradgleySEvansM, et al.
Assessing the risk of handling monoclonal antibodies. Hosp Pharm2008;
15: 60–64.
6.
MeadeE.Use of closed-system drug transfer devices in the handling and administration of MABs.Br J Nurs2015;
24: S21–27.
7.
NaranjoCABustoUSellersEM, et al.
A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther1981;
30: 239–245.
